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This commentary, sponsored by the National Mar-
row Donor Program (NMDP), reviews the current,
relevant data concerning the importance of HLA
matching in umbilical cord blood (UCB) transplanta-
tion (UCBT). Our goal is to provide guidance for
UCB unit selection and to identify the information
that is needed to refine the minimum and optimal
matching guidelines.
Background
The successful use of partially HLA-mismatched
unrelated donor UCB as a source of hematopoietic
stem cells (HSCs) was first reported by Kurtzberg
et al [1] in 1996. In the subsequent decade, several
studies have shown that the results of HSC transplants,
predominately in pediatric patients, using HLA
matched or partially mismatched unrelated donor
UCB, are comparable to those using unrelated donor
bone marrow [2-6]. UCB is now accepted as an alter-
native source of HSCs for unrelated donor transplan-
tation. There are currently over 47 public UCB banks
around the world that have a combined inventory of
over 260,000 UCB units (marrow.org and BMDW).
Over 8000 UCB transplants have been carried out
worldwide, and UCB is being increasingly utilized as
a source for HSC [7].Analyses of unrelated donor bone marrow trans-
plant (UBMT) outcomes have shown an impact of
HLA matching on outcomes such as hematopoietic
engraftment, graft-versus-host disease (GVHD), and
overall survival (OS). The following document sum-
marizes current data and provides guidance in select-
ing UCB units for unrelated donor UCBT based on
HLA matching. This commentary extends previous
guidelines from the NMDP on optimal donor-recipi-
ent matching for unrelated marrow transplants [8] to
include selection of unrelated donor UCB units. Be-
cause much of the data on the impact of HLA match
on UCBT is currently preliminary or inconclusive,
the NMDP will continue to monitor the literature
and research developments in the field to amend and
refine guidelines over time.
Assessment of HLA Match Status in UCBT Donor-
Recipient Pairs
When reviewing the cord blood transplant litera-
ture, it is important to note that the majority of
UCBTs reported have utilized matching at the antigen
level for HLA-A and HLA-B loci and at the allele level
for HLA-DRB1 loci. HLA-A and -B were typed either
by serology or low- to intermediate-resolution DNA-
based methods. In the first report of UCBT, prospec-
tive typing of UCB units for the DRB1 locus at the
allele level was carried out for UCB unit selection1
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able [1]. This approach was likely based on an early
recognition of the importance of DRB1 allele match-
ing in UBMT [9]. Donor-recipient matching was
thus categorized into 6/6, 5/6, 4/6, and greater
mismatching based on this level of resolution.
Recent studies in UBMT have identified the im-
portance of allelic disparity between donor and recip-
ient [10-13] in determining transplant outcomes.
Although HLA matching at low to intermediate reso-
lution for HLA-A and -B and allele level matching for
DRB1 continues to be the current standard for cord
blood unit selection, a number of recent retrospective
analyses have evaluated the impact of the undetected
allelic disparity in a subset of UCBT recipients [14-
17]. The NHLBI Cord Blood Transplantation Study
(COBLT) enrolled 316 pediatric patients at 28 trans-
plant centers. Of these, allele level typing was retro-
spectively determined for 292 pairs at HLA-A, -B,
and -DRB1 (6 alleles) and for 270 pairs at HLA-A,
-B, -DRB1, -C, and -DQB1 (10 alleles) [14]. Only
30% of pairs were found to be high-resolution HLA
matched at 8-10 alleles. In an analysis of a subset of
191 children with leukemia reported from the
COBLT patient cohort, HLA matching status was
subsequently demoted in 32% of recipient/donor pairs
after comparing the original to the final HLA match
[18].
The data from the study by Kogler et al [15] of 122
donor-recipient pairs showed significant changes in
HLA-A, -B, and -DRB1 match status between the ini-
tial assignments based on low-resolution testing of
HLA-A and -B and the allele level assignments for
HLA-A and -B. Over half (9 out of 16 patients)
thought to be 6/6 matched had lower levels of match
at the allele level. The number of patients receiving
less than 4/6 matched units almost doubled from 13
to 23 (11% to 19%). When additional HLA loci
such as HLA-C and HLA-DQB1, which have been
shown to be important in UBMT [10,19], were retro-
spectively determined, only 14% of patients were
matched for 9-10/10 alleles, 63% were matched for
6-8/10, and the remaining 23% were more extensively
mismatched. Similar levels of allelic disparity were
noted in the other 2 studies of UCBT [16,17]. For
comparison, evaluation of 1361 6/6 antigen matched
UBMTs showed that 29% of transplants were
matched at allele level for HLA-A, -B, and -DRB1
[20] compared to the much lower percent (6%) ob-
served in the smaller UCBT study of Kogler et al
[15]. There may be a selection bias in this comparison
because UCBT recipients are more likely to have less
common HLA types and less likely to have found
a BM donor match. The unidentified HLA disparity
is likely to impact the interpretation of the outcome
studies, and is a limitation in determining the current
role of HLA matching in UCBT studies.Impact of HLA Matching on Engraftment after
UCBT
Hematopoietic engraftment after UCBT differs
from that seen following either UBM or peripheral
blood stem cell transplantation in 2 important re-
spects. There is a significant delay in the time to en-
graftment (as measured by the time to recovery of an
absolute neutrophil count of .500/mL or time to
achievement of a platelet count of 20-50,000/mL inde-
pendent of transfusion support), and the overall prob-
ability of engraftment is lower compared to other stem
cell sources [2,3,5,6,18,21]. Studies of UCBT have
consistently shown that the cell dose is strongly corre-
lated with hematopoietic engraftment. Although the
total nucleated cell dose is a critical factor impacting
engraftment [22-24], additional studies have suggested
that the CD341 cell dose [25] or the graft progenitor
cell content as measured by colony-forming cells [26]
may be more important determinants of hematopoi-
etic recovery post-UCBT. However, as the quantifica-
tion of CD341 cells or colony-forming cells is difficult
to standardize from bank to bank, the nucleated cell
dose is more widely accepted as the criterion by which
UCB units are selected.
In addition to graft cell dose, analyses of outcomes
following UCBT have suggested an impact of donor-
recipient HLA matching on engraftment. Although
this was not seen in a smaller single institution study
of 102 recipients [25], in the largest analysis done to
date on 562 UCBT recipients, Rubinstein et al [22]
have shown that there is a progressive delay in myeloid
engraftment by day 42 with increasing HLA mis-
matching. In their analysis, 100% of patients receiving
HLA-A, -B, and -DRB1 matched transplants en-
grafted (n 5 40) compared to 78% (95% confidence
interval [CI], 72%-85%) of 211 recipients of 5/6
matched UCBT, 82% (95% CI, 76%-88%) of 257
recipients of 4/6 matched UCBT, and 69% (95%
CI, 52-86%) of 39 patients receiving grafts mis-
matched at 3 or more loci (P5 .01). The largest num-
ber of patients received grafts that were 1 or 2 antigen
mismatched, but the authors could not detect a signif-
icant difference in myeloid engraftment between those
who received grafts mismatched at 1 or 2 antigens. In
univariate analysis, platelet engraftment to a count of
50,000/microliter was not associated with the extent
of HLA disparity [22]. In the COBLT study, multivar-
iate analysis showed that a higher original HLA
match (5 or 6/6) correlated with neutrophil recovery
(P 5 .04) [18]. However, when the retrospective
HLA match was considered this correlation could
not be shown (P 5 .19).
The interaction of cell dose with HLA was not
evaluated in the COBLT study, but it has been ana-
lyzed in a recent study by Eapen et al [2] comparing
outcomes of 503 UCBTs and 282 UBMTs in children
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of both cell dose and HLA matching on outcome. A
cutoff for cell dose for 1 antigen mismatched trans-
plants was defined as 3  107/kg. Eapen et al [2] found
that the probability of neutrophil recovery by day 42
and platelet recovery by 6 months was similar after
marrow or matched UCBT but lower for mismatched
UCBT at both low and high cell doses compared
to UBMT. Higher cell doses resulted in a higher
probability of both neutrophil and platelet recovery
in 1 antigen-mismatched UCBT but had no effect in
2-antigen mismatched transplants, suggesting that
cell dose may not be able to overcome the adverse
impact of mismatching in the setting of 4 out of 6
matched UCBT.
An impact of HLA matching upon engraftment has
also been demonstrated by the the European Blood
and Marrow Transplant Group. In an analysis of 550
UCBTs, they found that the 60-day cumulative inci-
dence of neutrophil engraftment for all patients was
74%, whereas the incidence for those with no HLA
disparities versus $3 disparities were 83% and
53.2%, respectively (P 5 .001). The number of HLA
disparities was correlated with neutrophil recovery
with a log-linear relationship between HLA disparity
and risk of graft failure, suggesting inferior engraft-
ment with increased disparity. Only 263 of 550 pa-
tients (50.5%) achieved an untransfused platelet
count of 20,000/mL by day 180, with an absence of
both HLA-A, -B, and -DRB1 disparities being corre-
lated with a higher 180-day cumulative incidence of
platelet recovery (P5 .006). The EBMT study was un-
able to demonstrate a statistically significant interac-
tion between the cell dose and HLA disparities for
either neutrophil or platelet recovery [27].
In an analysis of the pooled datasets of the New
York Placental Blood Program, the National Marrow
Donor Program, and the COBLT Study, Gibbons an-
alyzed the effects of cell dose and HLA mismatch on
engraftment after UCBT and found that patients re-
ceiving HLA mismatched UCBT had a significantly
higher graft failure rate (P\ .001) than those receiving
6/6 matched cords (P\ .002 and P\ .007, respec-
tively, for patients with 4/6 and 5/6 mismatched
UCBT) [28]. In summary, whereas cell dose is impor-
tant for engraftment in UCBT, HLA match also ap-
pears to impact the engraftment rates. Table 1
summarizes the findings from the larger studies thatevaluated the impact of HLA match (antigen-level
HLA-A, -B, and allele-level HLA-DRB1) on
engraftment.
Impact of HLA Matching on GVHD
Several analyses of UCBT have assessed the impact
of HLA matching on GVHD incidence. The analysis
of the National Cord Blood Program of the New
York Blood Center’s experience showed that there
was a trend suggesting an impact of matching on risk
of severe grade III-IV GVHD with recipients of
matched UCB showing a lower GVHD risk compared
to recipients of mismatched UCB (P5 .06). There was
no impact of matching on chronic GVHD (cGVHD)
among recipients of mismatched UCB [22]. The anal-
ysis of Eurocord data shows that whereas the degree of
matching did not impact overall GVHD risk, the risk
of grade III-IV GVHD was higher in recipients of
UCB where class I and II disparities coexisted between
donor and recipient [27]. In the COBLT study, multi-
variate analysis of the impact of the original HLA
matching (intermediate resolution at class I and allele
level at class II) on incidence of acute GVHD
(aGVHD) showed that HLA matching impacted grade
II-IV risk with a significantly higher risk of aGVHD in
recipients of 4/6 matched UCB compared to 5-6/6
matched UCB (P 5 .03) [18]. The outcome compari-
son study of UBM versus UCB by Eapen et al [2]
showed a significantly higher risk of both aGVHD
and cGVHD with the use of matched BM compared
to UCB, but failed to show a correlation between
HLA match and aGVHD or cGVHD risk among re-
cipients of UCB transplants. Table 2 summarizes the












6/6 100% 83% 85% Favorable
(P 5 .04)§
5/6 78% (NS) Decrease (NS) 80%
4/6 82% (NS) Decrease (NS) 76% Unfavorable




§Multivariate analysis results comparing$5/6 to#4/6; hazard ratio
1.39 95%CI (1.02-1.89). P 5 .04.Table 2. HLA Match: Effect of Mismatching on GVHD
Impact of HLA
Match on GVHD Rubinstein et al22 Gluckman et al27 Eapen et al2 Kurtzberg et al18
Acute GVHD \6/6 match increases
grade III-IV risk (P 5 .06)
Increased risk of grade
III-IV with class I and
class II mismatch
No impact \5/6 match increases grade
II-IV risk (P 5 .03)
Chronic GVHD No impact Not evaluated No impact Not evaluated
4 N. Kamani et al.findings from the larger studies that evaluated the im-
pact of HLA match (antigen-level HLA-A, B, and al-
lele-level HLA-DRB1) on GVHD and the findings
from studies that evaluated the impact of HLA match
on aGVHD and/or cGVHD.
Role of HLA Compatibility on Survival after UCBT
Only a few reports of UCBT have analyzed the ef-
fects of HLA mismatching on patient survival. Rubin-
stein et al [22], and later Wagner et al [25], reported
the association of HLA-mismatching with the out-
come of UCBT. Both reports identified the detrimen-
tal effects of HLA-A, -B, and -DRB1 mismatching on
survival. Rubinstein et al [22] found that event-free
survival (EFS) (with event defined by death, autolo-
gous reconstitution, or second transplant) was associ-
ated with HLA incompatibility (P5 .004 in univariate
analysis). A multivariable Cox model analysis found
a higher risk of these adverse events in 217 UCBTs
with 1 mismatch (relative risk [RR] 5 2.0, 95% CI
1.1-3.6), and 300 UCBTs with 2 or more mismatches
(RR 5 2.5, 95% CI 1.4-4.5) compared with 40
matched cord blood transplants. Although the power
of the study was limited, there was no significant effect
of the number of mismatched loci, type of mismatched
locus, and level of typing resolution utilized to define
the mismatch at DRB1. Wagner et al [25] found an in-
creased risk of death (RR 5 2.4, 95% CI 1.2-4.7)
among 44 recipients of UCBTs mismatched for 2-3
loci, compared to 58 mismatched for 0-1 locus (multi-
variable P 5 .01). Eapen et al [2] evaluated treatment
failure as the inverse of leukemia-free survival (LFS)
and showed a favorable outcome for matched UCBT
compared to 1 to 2 antigen mismatched UCBT or
matched or allele-mismatched UBMT (P 5 .041). It
is to be noted that there were only 35 patients in the
matched UCB cohort, but suggests that HLA match-
ing may be of strong import in outcome after UCBT.
In contrast to the reports by Rubinstein et al [22]
and Wagner et al [25], a study of 550 UCBTs by Euro-
cord [27] failed to find an effect of HLA disparity on
3-year survival with estimates of 34% with an HLA-
A, -B, -DRB1 match (n 5 53), 38% with 1 mismatch
(n 5 243), 32% with 2 mismatches (n 5 218), and
33% with 3 or 4 mismatches (n 5 36) (P 5 .30). The
reasons why these results were discordant with thosefrom the Rubinstein et al [22] and Wagner et al [25]
studies are not obvious; however, cell dose did not en-
ter the multivariable model in the Eurocord study,
whereas it was significant and was retained in the
multivariable models of both the Rubinstein et al [22]
and Wagner et al [25] studies. It should be noted that
in the Eurocord analysis of patients with malignant dis-
eases, increasing HLA disparity resulted in lower rates
of engraftment and higher treatment-related mortality
(TRM) and cGVHD, but this did not translate into
a lower disease-free (DFS) or OS because of a lower
relapse rate. HLA disparity did impact survival for
patients with nonmalignant diseases [7].
It has been proposed that a higher graft cell dose is
required for engraftment and survival after mis-
matched than after matched UCBTs. TRM was signif-
icantly lower among patients who received 1 antigen
mismatched UCB and a relatively high cell dose
(.30 million total nucleated cells [TNCs] per kg),
whereas those who received 1 antigen mismatched
UCB and a lower cell dose or recipients of 2 antigen
mismatched UCB regardless of cell dose had higher
TRM. This effect did not translate into a higher LFS
for recipients of higher cell dose 1 antigen mismatched
UCBT [2]. Because the effects of HLA-mismatching
and cell dose appear to interact, it is possible that the
potential effect of HLA may be masked if cell dose is
not considered in the analysis. Table 3 summarizes
the findings of the largest studies to date that evaluated
the role of HLA match on survival following UCBT.
The impact of high-resolution HLA matching in
UCBT has been investigated in a number of papers.
Ohnuma et al [16] reported that mismatching for 2-4
HLA-A, B, or DRB1 alleles (n 5 13) was associated
with decreased survival (35% versus 75%) compared
to mismatching for 0-1 alleles (n5 14) (P5 .02). Cor-
netta et al [17] reported no effect of HLA-mismatching
at low resolution on the 1-year survival in a small study
of 24 adults. When high-resolution typing was used to
define HLA-A, -B, and -DRB1 alleles, 3 of 4 patients
with 0-1 mismatches survived .1 year compared to 2
of 20 patients with 2 or 3 mismatches. Both these anal-
yses suggest that high-resolution HLA typing may
help select UCB units better suitable for a favorable
outcome.
Kogler et al [15] retrospectively typed 122 UCBT
donor and recipient pairs by high resolution atTable 3. HLA Match: Effect of Mismatching on Survival
HLA-A, B, DRB1 match
status* Rubinstein et al22 Wagner et al25 Gluckman et al27 Eapen et al2‡ Kurtzberg et al18
5/6 Decrease Decrease No effect† Decrease Not evaluated
# 4/6 Decrease Decrease No effect† Decrease Decrease
*Mismatch count based on antigen-level match at HLA-A, -B, and allele-level at HLA-DRB1.
†Cell dose was not considered in the multivariate analysis.
‡Leukemia free survival.
NMDP Cord-Matching Guidelines 5HLA-A, -B, -C, -DRB1, and -DQB1, but failed to
show any association with survival in univariate analy-
ses. A multivariable model including cell dose as cova-
riate was not shown in the paper, and therefore the
potential confounding interaction of cell dose with
HLA-mismatching might have masked a possible asso-
ciation of HLA mismatching with survival. In the
COBLT study, multivariate analysis using retrospec-
tive high-resolution typing data showed that there
was a significant increase in the incidence of grades
II-IV and III-IV acute GVHD (P5 .02) and a signifi-
cant decrease in survival probability when a 2-4/6
matched UCBT was compared to 5-6/6 matched
transplants (P 5 .04) [18].
When interpreting all the analyses described
above, the following limitations need to be kept in
mind. First, only a small proportion of patients have
received fully matched UCB transplants, and most of
them have been pediatric patients. Second, the major-
ity of transplants performed to date have been 1 or 2
antigen mismatched, and larger patient numbers may
be required to fully determine the differences between
these 2 cohorts. Third, although there are suggestions
of an interaction between cell dose and HLA match-
ing, the sample sizes thus far have limited the investi-
gation of this interaction. In addition, patient age
and cell dose may be confounding variables.
Other Considerations in UCB Unit Selection
Although the availability of adequately dosed and
HLA-matched UCB units is important, there are
a number of other factors that need to be considered
when selecting a unit for transplant. A number of ad-
ditional factors may influence how a transplant physi-
cian chooses UCB units including: the CB bank,
whether the unit was red cell depleted prior to cryo-
preservation, and availability of attached segments for
confirmatory typing and infectious disease marker
characteristics of the unit. There are no data cur-
rently available, however, that have evaluated the
role of these in engraftment or survival after UCB
transplantation.
SUMMARY
UCB graft cell dose is a critical determinant of he-
matopoietic recovery and survival after UCBT. How-
ever, there is increasing evidence that HLA match is
also a key factor in UCBT outcome with mismatch ad-
versely impacting on both engraftment and survival.
Because of the relatively low numbers of patients trans-
planted with UCB to date it is not currently known
how cell dose and HLA match interact as determinants
of UCBT outcome. Also, it is not clear whether the
same criteria will apply to both pediatric and adult re-
cipients. Current data suggest that HLA match is crit-
ically important in the setting of a low cell dose. Theelucidation of the impact of cell dose and match on
UCBT outcome will be a major research priority for
the future, and may impact determinations of the size
of the cord blood inventory. Specifically, the available
data does not allow us to fully discern the impact of a 1
versus 2 antigen mismatch, or how to ‘‘trade-off’’ the
HLA-match and cell dose in unit selection. In addi-
tion, the importance of allele level matching at HLA-
A and B, the match vector, and whether HLA-C or
DQB1 should be considered in the selection of UCB
units for transplantation is yet to be determined, and
will rely on the collection of the appropriate allele level
data to permit future analyses. The interaction be-
tween cell dose and HLA matching is especially critical
in adults undergoing UCBT, and underlines the need
for drastic increases in the unrelated cord blood inven-
tory. Table 4 summarizes the NMDP’s current recom-
mendations for typing and matching of UCB units for
transplantation based on the current literature. All rec-
ommendations are based on selection of a unit with an
appropriate cell dose. Currently available data would
consider this to be a unit that has .2.5-3  107 total
precryopreserved nucleated cells per kg recipient
body weight. It is hoped, however, that an increased
UCB inventory will allow patients to receive units
that are both of better match and sufficient cell dose,
and that this will result in improved hematopoietic
engraftment and survival after UCBT.
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